LENOIR, N.C.--(BUSINESS WIRE)--Greer, a leading developer and provider of allergy immunotherapy products and services, has completed enrollment for its pivotal Phase III clinical trial designed to study the efficacy of sublingual-oral immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. It is estimated that 30 million Americans are allergic to short ragweed pollen, making it one of the most common allergens.
